Mylan gets FDA OK to market Levothyroxine sodium tablets

Wed Jan 3, 2007 9:46am EST
 
[-] Text [+]

Jan 3 (Reuters) - Mylan Laboratories Inc. MYL.N, a maker of generic drugs, said it received U.S. Food and Drug Administration approval to market Levothyroxine sodium tablets as a bioequivalent to Levothroid tablets, which treats deficiency of thyroid activity.

Mylan said in a statement that Levothyroxine sodium tablets are approved to treat hypothyroidism and pituitary TSH suppression. (Reporting by Dilipp S. Nag in Bangalore)

 
Join the Reuters Consumer Insight Panel and help us get to know you better

Join the Reuters Consumer Insight Panel and help us get to know you better